| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 620 | 323 | 853 | 564 | 571 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 189 | 627 | 445 | 435 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 222 | 133 | 226 | 118 | 137 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 34 % | 38 % | 25 % | 19 % | 22 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 20 | 54 | 45 | 44 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 10 | 3 | 10 | 10 | 9 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 174 | 110 | 161 | 63 | 84 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 36 | 26 | 44 | 16 | 17 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 83 | 117 | 46 | 66 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.63 | 3.26 | 3.16 | 1.28 | 1.94 |
Cohance Lifesciences
Cohance Lifesciences
542.55
-6.55
(-1.19%)
Market Cap
₹20,756.20 Cr
PE Ratio
71.04
Volume
3,45,767.00
Day High - Low
₹548.90 - ₹533.55
52W High-Low
₹1,342.00 - ₹540.35
There are 1 new updates from the company20 hours ago
View
Key Fundamentals
Market Cap
20,756.20 Cr
EPS
10.52
PB Ratio
5.88
Book Value
99.01
EBITDA
433.80
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from8 analysts
Actual
Company News
View All News
Cohance Lifesciences Appoints Three Senior Management Personnel20 hours ago
Cohance Lifesciences appointed Gunjan Singh as Business Head API plus, Amrit Singh as Head-Specialty Chemicals, and Ravinatha Shetty as Platform Chief Operating Officer, all effective December 5, 2025. The appointments strengthen the company's leadership across API, specialty chemicals, and operations divisions with executives bringing over 20-35 years of industry experience from leading pharmaceutical companies.
Cohance Lifesciences Receives IND AA/Stable Credit Rating on INR 6,850 Million Bank Facilities2 days ago
India Ratings and Research assigned an IND AA/Stable rating to Cohance Lifesciences Limited's bank loan facilities worth INR 6,850 million. The rating covers various facilities including term loans and working capital limits across multiple banks including State Bank of India, Axis Bank, ICICI Bank, and others.
Cohance Lifesciences Limited's Nomination and Remuneration Committee approved the grant of 80,15,626 stock options to eligible employees under the Employee Stock Option Plan 2023. The options will vest between 1-10 years from grant date and can be exercised within 3 years of vesting, with each option carrying the right to one equity share of Re. 1 face value.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,805.30 | #1 4,33,151.90 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 63.65 | |
6,473.50 | 1,71,851.10 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.10 | |
3,785.90 | 1,28,132.10 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 60.01 | |
1,520.80 | 1,22,843.20 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.01 | |
1,275.20 | 1,06,429.90 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 61.42 | |
2,098.80 | 95,863.60 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 67.65 | |
931.45 | 93,725.70 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 40.18 | |
2,205.50 | 91,033.90 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 32.30 | |
1,217.60 | 70,718.40 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 58.88 | |
5,675.50 | 67,859.10 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.12 |
Growth Rate
Revenue Growth
12.83 %
Net Income Growth
-11.82 %
Cash Flow Change
-19.62 %
ROE
-1.78 %
ROCE
-30.56 %
EBITDA Margin (Avg.)
-17.81 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 889 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 256 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 726 |
| Total Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 365 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 826 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 1,841 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -253 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 359 | 288 |
| Financing Activities | 26 | 7 | -76 | -156 | -242 | -14 | 3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % | 57.49 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % | 6.51 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % | 20.82 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % | 6.42 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % | 8.75 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 | 75,284 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 |  Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
| 19 Sept 2025 | Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 912.70 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 869.30 | 691.30 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
20 hours ago
20 hours agoAnnouncement under Regulation 30 (LODR)-Credit Rating2 days ago
2 days agoGrant Of Stock Options2 days ago
2 days agoGeneral Updates3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 24, 2025
Nov 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Nov 12, 2025Outcome Of The MeetingNov 12, 2025
Nov 12, 2025Board Meeting Outcome for Outcome Of The Board MeetingNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 01, 2025
Nov 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Oct 28, 2025General UpdateOct 26, 2025
Oct 26, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 27, 2025
Sep 27, 2025Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ending September 30 2025.Sep 27, 2025
Sep 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 24, 2025
Sep 24, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 22, 2025
Sep 22, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Sep 22, 2025
Sep 22, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 19, 2025
Sep 19, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 19, 2025
Sep 19, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 19, 2025
Sep 19, 2025Clarification On Reported News In Electronic MediaSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Sep 18, 2025Disclosure Under SEBI PIT RegulationsSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Sep 15, 2025Completion Of USFDA InspectionSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 07, 2025
Sep 07, 2025Letter To Shareholders Regarding Annual ReportAug 28, 2025
Aug 28, 2025General AnnouncementAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Credit RatingAug 27, 2025
Aug 27, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Aug 26, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Notice Of AGMAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Completion Of USFDA InspectionAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Mutual Fund Holdings
HDFC Flexi Cap Direct Plan-Growth 
Invesco India Contra Fund Direct-Growth 
DSP ELSS Tax Saver Fund Direct Plan-Growth 
SBI Mid Cap Direct Plan-Growth 
Axis Small Cap Fund Direct-Growth 
Canara Robeco Small Cap Fund Direct - Growth 
UTI Flexi Cap Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Aditya Birla Sun Life Mid Cap Direct Fund-Growth 
360 ONE Focused Fund Direct-Growth 
Mirae Asset Healthcare Fund Direct - Growth Technical Indicators
RSI(14)
Oversold 18.37
ATR(14)
Less Volatile 20.48
STOCH(9,6)
Oversold 10.82
STOCH RSI(14)
Neutral 79.10
MACD(12,26)
Bullish 5.01
ADX(14)
Very Strong Trend 62.07
UO(9)
Bearish 34.67
ROC(12)
Downtrend And Accelerating -6.82
WillR(14)
Oversold -89.22
About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
